Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1006203

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many adverse ovarian hypersensitivity syndrome incidents were recorded in licensed human fertilisation embryology authority clinics between 2011 and 2018; and what the severity grading of each such incident was.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	190847
answer	answer is ministerial correction date of answer 19/11/2018 answer text <p>The Human Fertilisation and Embryology Act 1990 requires the Human Fertilisation and Embryology Authority (HFEA) to investigate all serious adverse events that take place in its licensed establishments and all serious adverse reactions to treatment suffered by patients. The conditions of a HFEA licence require Persons Responsible at licensed establishments to report all serious adverse events, including near misses, and reactions to the HFEA. Licensed establishments are required to report any serious adverse reactions to treatment, that they are made aware of, even if the patient is no longer receiving fertility treatment. There is no duty on any other medical establishment to make reports to the HFEA.</p><p> </p><p>Cases of severe or critical Ovarian Hyperstimulation Syndrome (OHSS) are considered to be serious adverse reactions to treatment. The information requested is shown in the following table:</p><table><tbody><tr><td><p><strong> </strong></p></td><td><p>Mild*</p></td><td><p>Mild/moderate*</p></td><td><p>Moderate*</p></td><td><p>Moderate*/severe</p></td><td><p>Severe</p></td><td><p>Critical</p></td></tr><tr><td><p>2011</p></td><td><p>96</p></td><td><p>21</p></td><td><p>65</p></td><td><p>9</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td><p>2012</p></td><td><p>41</p></td><td><p>20</p></td><td><p>93</p></td><td><p>10</p></td><td><p>33</p></td><td><p>0</p></td></tr><tr><td><p>2013</p></td><td><p>40</p></td><td><p>22</p></td><td><p>85</p></td><td><p>7</p></td><td><p>46</p></td><td><p>0</p></td></tr><tr><td><p>2014</p></td><td><p>41 (one intrauterine insemination)</p></td><td><p>8</p></td><td><p>50</p></td><td><p>14</p></td><td><p>34</p></td><td><p>0</p></td></tr><tr><td><p>2015</p></td><td><p>20</p></td><td><p>8</p></td><td><p>42</p></td><td><p>11</p></td><td><p>56</p></td><td><p>0</p></td></tr><tr><td><p>2016</p></td><td><p>29</p></td><td><p>12</p></td><td><p>46</p></td><td><p>5</p></td><td><p>40</p></td><td><p>0</p></td></tr><tr><td><p>2017</p></td><td><p>24</p></td><td><p>11</p></td><td><p>42</p></td><td><p>7</p></td><td><p>47</p></td><td><p>0</p></td></tr><tr><td><p>2018 (to 14 November 2018)</p></td><td><p>14</p></td><td><p>7</p></td><td><p>27</p></td><td><p>5</p></td><td><p>75</p></td><td><p>0</p></td></tr></tbody></table><p>Source: HFEA</p><p> </p><p>Notes:</p><ol><li>The HFEA only requires clinics to report cases of severe or critical OHSS, although some clinics do report mild through to moderate cases. For that reason, this is not a complete picture of the occurrence of OHSS.</li><li>The HFEA has advised that it believes the increase in the number of reports of severe OHSS in 2018 is the result of clearer guidance in its code of practice, linking to the Royal College of Obstetricians and Gynaecologists’ “Green Top” guidance on OHSS that includes a severity grading definition</li></ol><p> </p><p>Identifying patient information, held on the HFEA’s register, can only be disclosed without the patient’s consent in very limited circumstances. The Government has no plans to lift those restrictions to enable the data to be routinely linked with other health or mortality registers.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 190845 190848 question first answered 19/11/2018 17:42:50 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3958 label Biography information for Fiona Bruce

770046

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many women were admitted to hospital with severe ovarian hyperstimulation syndrome following IVF treatment in (a) 2015 and (b) 2016.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107676
answer	answer is ministerial correction date of answer 18/10/2017 answer text <p>NHS Digital has advised that this data is not collected centrally.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 18/10/2017 14:22:17 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

770058

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents involving ovarian hyper stimulation syndrome were recorded in licensed HFEA clinics in each year since 2011; and what the severity grading was of each such incident.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107657
answer	answer is ministerial correction date of answer 23/10/2017 answer text <p>The Human Fertilisation and Embryology Authority has advised that it only requires clinics to report cases of severe or critical ovarian hyper stimulation syndrome. There were no Grade A (critical) incidents reported in this time period.</p><table><tbody><tr><td><p>Grade</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2014</p></td><td><p>2015</p></td><td><p>2016</p></td></tr><tr><td><p>B</p></td><td><p>56</p></td><td><p>33</p></td><td><p>43</p></td><td><p>40</p></td><td><p>60</p></td><td><p>38</p></td></tr></tbody></table> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 23/10/2017 11:15:31 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

770059

registered interest
date	13/10/2017
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many women have died from ovarian hyperstimulation syndrome in each year since 2011.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107658
answer	answer is ministerial correction date of answer 20/10/2017 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I<br>have asked the Authority to reply.</p> answering member constituency Kingswood answering member printed Chris Skidmore question first answered 20/10/2017 14:55:41 answering member 4021 label Biography information for Chris Skidmore attachment 1 file name 107658 v.02.pdf title UKSA response
tabling member	3958 label Biography information for Fiona Bruce

770060

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many non-patient donors who had ovarian hyperstimulation syndrome were categorised as grade (a) A and (b) B in each year for which information is available.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107659
answer	answer is ministerial correction date of answer 23/10/2017 answer text <p>This information is not collected. The Human Fertilisation and Embryology Authority has advised that it does not require licensed fertility clinics to differentiate between patient or non-patient donor incidents.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 107660 question first answered 23/10/2017 11:27:17 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

770063

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many non-patient egg donors were admitted to hospital for ovarian hyperstimulation syndrome in each year for which figures are available.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107660
answer	answer is ministerial correction date of answer 23/10/2017 answer text <p>This information is not collected. The Human Fertilisation and Embryology Authority has advised that it does not require licensed fertility clinics to differentiate between patient or non-patient donor incidents.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne grouped question UIN 107659 question first answered 23/10/2017 11:27:17 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

770066

registered interest
date	13/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the level of data his Department has collected on ovarian hyperstimulation syndrome has been in each year since 2010.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	107663
answer	answer is ministerial correction date of answer 23/10/2017 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that since 2010, it has required licensed clinics, under the HFEA’s Code of Practice, General Directions 0011, to report all adverse incidents, which includes severe ovarian hyperstimulation syndrome.</p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 23/10/2017 11:25:23 answering member 1542 label Biography information for Philip Dunne
tabling member	3958 label Biography information for Fiona Bruce

668994

registered interest
date	06/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many incidents of hospitalisation due to ovarian hyperstimulation syndrome have been reported to the Human Fertilisation and Embryology Authority (HFEA); and what steps the HFEA is taking to ensure that all suspected serious adverse reactions are reported to the Medicines and Healthcare Products Regulatory Agency.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	58664
answer	answer is ministerial correction date of answer 16/01/2017 answer text <p>The information on the number of incidents of hospitalisation and adverse incidents due to ovarian hyperstimulation syndrome (OHSS) reported to the Human Fertilisation and Embryology Authority (HFEA) could only be obtained at disproportionate cost.</p><p> </p><p>The HFEA has advised that severe or critical cases of OHSS are treated as adverse incidents. A clinic must submit an incident report to the HFEA whenever it is made aware of a case of OHSS requiring a hospital admission, that has a severity grading of severe or critical. The HFEA would expect the clinic to review the patient’s drug stimulation regime, treatment and predisposing factors for OHSS, and to revise its practice and protocols where appropriate. This review is expected to be submitted to the HFEA within 10 working days from the date the incident was reported. The clinic’s report is reviewed by the Authority’s inspectorate and the clinical governance lead and, where appropriate, further enforcement action may be taken or relevant authorities contacted. Should there be unexpected adverse drug reactions not associated with a particular drug regime, these should be reported to Medicines and Healthcare Products Regulatory Agency (MHRA), by the patient’s clinician, under the MHRA’s Yellow Card scheme.</p><p> </p><p>The Yellow Card scheme enables clinicians to help improve medicines safety by reporting all suspected adverse drug reactions to MHRA. The scheme is focused on healthcare professionals and patients rather than regulatory bodies. The HFEA does not separately report adverse drug reactions to MHRA.</p><p> </p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 58673 58674 question first answered 16/01/2017 17:16:13 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3958 label Biography information for Fiona Bruce

668997

registered interest
date	06/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many adverse incidents due to ovarian hyperstimulation syndrome have been reported by the Human Fertilisation and Embryology Authority to the Medicines and Healthcare Products Regulatory Agency in each year since 1991.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	58673
answer	answer is ministerial correction date of answer 16/01/2017 answer text <p>The information on the number of incidents of hospitalisation and adverse incidents due to ovarian hyperstimulation syndrome (OHSS) reported to the Human Fertilisation and Embryology Authority (HFEA) could only be obtained at disproportionate cost.</p><p> </p><p>The HFEA has advised that severe or critical cases of OHSS are treated as adverse incidents. A clinic must submit an incident report to the HFEA whenever it is made aware of a case of OHSS requiring a hospital admission, that has a severity grading of severe or critical. The HFEA would expect the clinic to review the patient’s drug stimulation regime, treatment and predisposing factors for OHSS, and to revise its practice and protocols where appropriate. This review is expected to be submitted to the HFEA within 10 working days from the date the incident was reported. The clinic’s report is reviewed by the Authority’s inspectorate and the clinical governance lead and, where appropriate, further enforcement action may be taken or relevant authorities contacted. Should there be unexpected adverse drug reactions not associated with a particular drug regime, these should be reported to Medicines and Healthcare Products Regulatory Agency (MHRA), by the patient’s clinician, under the MHRA’s Yellow Card scheme.</p><p> </p><p>The Yellow Card scheme enables clinicians to help improve medicines safety by reporting all suspected adverse drug reactions to MHRA. The scheme is focused on healthcare professionals and patients rather than regulatory bodies. The HFEA does not separately report adverse drug reactions to MHRA.</p><p> </p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 58664 58674 question first answered 16/01/2017 17:16:13 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3958 label Biography information for Fiona Bruce

668998

registered interest
date	06/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps are being taken to mitigate the risks of ovarian hyperstimulation syndrome.
tabling member constituency	Congleton
tabling member printed	Fiona Bruce
uin	58674
answer	answer is ministerial correction date of answer 16/01/2017 answer text <p>The information on the number of incidents of hospitalisation and adverse incidents due to ovarian hyperstimulation syndrome (OHSS) reported to the Human Fertilisation and Embryology Authority (HFEA) could only be obtained at disproportionate cost.</p><p> </p><p>The HFEA has advised that severe or critical cases of OHSS are treated as adverse incidents. A clinic must submit an incident report to the HFEA whenever it is made aware of a case of OHSS requiring a hospital admission, that has a severity grading of severe or critical. The HFEA would expect the clinic to review the patient’s drug stimulation regime, treatment and predisposing factors for OHSS, and to revise its practice and protocols where appropriate. This review is expected to be submitted to the HFEA within 10 working days from the date the incident was reported. The clinic’s report is reviewed by the Authority’s inspectorate and the clinical governance lead and, where appropriate, further enforcement action may be taken or relevant authorities contacted. Should there be unexpected adverse drug reactions not associated with a particular drug regime, these should be reported to Medicines and Healthcare Products Regulatory Agency (MHRA), by the patient’s clinician, under the MHRA’s Yellow Card scheme.</p><p> </p><p>The Yellow Card scheme enables clinicians to help improve medicines safety by reporting all suspected adverse drug reactions to MHRA. The scheme is focused on healthcare professionals and patients rather than regulatory bodies. The HFEA does not separately report adverse drug reactions to MHRA.</p><p> </p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood grouped question UIN 58664 58673 question first answered 16/01/2017 17:16:13 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	3958 label Biography information for Fiona Bruce